Biosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...
Read moreAre we one step closer to an EU Health Technology Assessment body. The EESC publish its positive opi...
Read moreThere is a large opportunity many companies are still yet to seize in this area.
Read moreSecuring patient access in specialty products is becoming increasingly challenging due to the comple...
Read moreRemap Consulting has significant expertise in guiding companies through both EUnetHTA / EMA Parallel...
Read moreWithin the last few months, the significant changes proposed to the Italian pricing and reimbursemen...
Read moreTo tackle antibiotic resistance, novel antibiotics are being reserved as later-line therapy for more...
Read moreRemap Consulting recently attended an ISPOR webinar discussing the digital health ecosystem in APAC ...
Read moreChina has the second largest healthcare system in the world. However, this market has been challengi...
Read moreFor an audience to properly understand the value of a drug, evidence needs to be put into context.
Read more